• Je něco špatně v tomto záznamu ?

Structure-Activity Relationship of para-Carborane Selective Estrogen Receptor β Agonists

D. Sedlák, TA. Wilson, W. Tjarks, HS. Radomska, H. Wang, JN. Kolla, ZJ. Leśnikowski, A. Špičáková, T. Ali, K. Ishita, LH. Rakotondraibe, S. Vibhute, D. Wang, P. Anzenbacher, C. Bennett, P. Bartunek, CC. Coss

. 2021 ; 64 (13) : 9330-9353. [pub] 20210628

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025384

Grantová podpora
P30 CA016058 NCI NIH HHS - United States

Selective agonism of the estrogen receptor (ER) subtypes, ERα and ERβ, has historically been difficult to achieve due to the high degree of ligand-binding domain structural similarity. Multiple efforts have focused on the use of classical organic scaffolds to model 17β-estradiol geometry in the design of ERβ selective agonists, with several proceeding to various stages of clinical development. Carborane scaffolds offer many unique advantages including the potential for novel ligand/receptor interactions but remain relatively unexplored. We synthesized a series of para-carborane estrogen receptor agonists revealing an ERβ selective structure-activity relationship. We report ERβ agonists with low nanomolar potency, greater than 200-fold selectivity for ERβ over ERα, limited off-target activity against other nuclear receptors, and only sparse CYP450 inhibition at very high micromolar concentrations. The pharmacological properties of our para-carborane ERβ selective agonists measure favorably against clinically developed ERβ agonists and support further evaluation of carborane-based selective estrogen receptor modulators.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025384
003      
CZ-PrNML
005      
20211026133852.0
007      
ta
008      
211013s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.jmedchem.1c00555 $2 doi
035    __
$a (PubMed)34181409
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sedlák, David $u CZ-OPENSCREEN, Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic
245    10
$a Structure-Activity Relationship of para-Carborane Selective Estrogen Receptor β Agonists / $c D. Sedlák, TA. Wilson, W. Tjarks, HS. Radomska, H. Wang, JN. Kolla, ZJ. Leśnikowski, A. Špičáková, T. Ali, K. Ishita, LH. Rakotondraibe, S. Vibhute, D. Wang, P. Anzenbacher, C. Bennett, P. Bartunek, CC. Coss
520    9_
$a Selective agonism of the estrogen receptor (ER) subtypes, ERα and ERβ, has historically been difficult to achieve due to the high degree of ligand-binding domain structural similarity. Multiple efforts have focused on the use of classical organic scaffolds to model 17β-estradiol geometry in the design of ERβ selective agonists, with several proceeding to various stages of clinical development. Carborane scaffolds offer many unique advantages including the potential for novel ligand/receptor interactions but remain relatively unexplored. We synthesized a series of para-carborane estrogen receptor agonists revealing an ERβ selective structure-activity relationship. We report ERβ agonists with low nanomolar potency, greater than 200-fold selectivity for ERβ over ERα, limited off-target activity against other nuclear receptors, and only sparse CYP450 inhibition at very high micromolar concentrations. The pharmacological properties of our para-carborane ERβ selective agonists measure favorably against clinically developed ERβ agonists and support further evaluation of carborane-based selective estrogen receptor modulators.
650    _2
$a sloučeniny boru $x chemická syntéza $x chemie $x farmakologie $7 D001896
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a beta receptor estrogenů $x agonisté $7 D047629
650    _2
$a estrogeny $x chemická syntéza $x chemie $x farmakologie $7 D004967
650    _2
$a HEK293 buňky $7 D057809
650    _2
$a lidé $7 D006801
650    _2
$a molekulární struktura $7 D015394
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Wilson, Tyler A $u Medicinal Chemistry Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States
700    1_
$a Tjarks, Werner $u Division of Medicinal Chemistry and Pharmacognosy College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
700    1_
$a Radomska, Hanna S $u Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
700    1_
$a Wang, Hongyan $u Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
700    1_
$a Kolla, Jayaprakash Narayana $u CZ-OPENSCREEN, Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic
700    1_
$a Leśnikowski, Zbigniew J $u Laboratory of Medicinal Chemistry, Institute of Medical Biology PAS, 106 Lodowa Street, 93-232 Lodz, Poland
700    1_
$a Špičáková, Alena $u Department of Pharmacology, Faculty of Medicine, Palacky University, Hněvotínská 3, 77515 Olomouc, Czech Republic
700    1_
$a Ali, Tehane $u Division of Medicinal Chemistry and Pharmacognosy College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
700    1_
$a Ishita, Keisuke $u Division of Medicinal Chemistry and Pharmacognosy College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
700    1_
$a Rakotondraibe, Liva Harinantenaina $u Division of Medicinal Chemistry and Pharmacognosy College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States
700    1_
$a Vibhute, Sandip $u Medicinal Chemistry Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States
700    1_
$a Wang, Dasheng $u Medicinal Chemistry Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States
700    1_
$a Anzenbacher, Pavel $u Department of Pharmacology, Faculty of Medicine, Palacky University, Hněvotínská 3, 77515 Olomouc, Czech Republic
700    1_
$a Bennett, Chad $u Medicinal Chemistry Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States $u Drug Development Institute, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States
700    1_
$a Bartunek, Petr $u CZ-OPENSCREEN, Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic
700    1_
$a Coss, Christopher C $u Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States $u Drug Development Institute, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, United States
773    0_
$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 64, č. 13 (2021), s. 9330-9353
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34181409 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133858 $b ABA008
999    __
$a ok $b bmc $g 1714429 $s 1145891
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 64 $c 13 $d 9330-9353 $e 20210628 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
GRA    __
$a P30 CA016058 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace